Chlorthalidone for Resistant Hypertension in Advanced Chronic Kidney Disease

Rajiv Agarwal^{1

2}, Arjun D Sinha^{1

2}, Wanzhu Tu^{3

4}

Affiliations

¹ Division of Nephrology, Department of Medicine (R.A., A.D.S.), Indiana University School of Medicine, Indianapolis.
² Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN (R.A., A.D.S.).
³ Department of Biostatistics & Health Data Science, Richard M. Fairbanks School of Public Health, Indiana University Center for Aging Research (W.T.), Indiana University School of Medicine, Indianapolis.
⁴ Regenstrief Institute, Indianapolis, IN (W.T.).

Rajiv Agarwal et al. Circulation. 2022.

. 2022 Aug 30;146(9):718-720.

doi: 10.1161/CIRCULATIONAHA.122.060167. Epub 2022 Aug 29.

Rajiv Agarwal^{1

2}, Arjun D Sinha^{1

2}, Wanzhu Tu^{3

4}

¹ Division of Nephrology, Department of Medicine (R.A., A.D.S.), Indiana University School of Medicine, Indianapolis.
² Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN (R.A., A.D.S.).
³ Department of Biostatistics & Health Data Science, Richard M. Fairbanks School of Public Health, Indiana University Center for Aging Research (W.T.), Indiana University School of Medicine, Indianapolis.
⁴ Regenstrief Institute, Indianapolis, IN (W.T.).

No abstract available

References

1. De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, Nappi F, Conte G and Minutolo R. Prevalence and Prognostic Role of Resistant Hypertension in Chronic Kidney Disease Patients. Journal of the American College of Cardiology. 2013;61:2461–2467. - PubMed
1. Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F and Tu W. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med. 2021;385:2507–2519. - PMC - PubMed
1. Nishizaka MK, Zaman MA and Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925–30. - PubMed
1. Bolignano D, Palmer SC, Navaneethan SD and Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014:CD007004. - PubMed
1. Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White WB and Williams B. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:1540–1550. - PubMed